Company Overview

Avicanna Inc. is a Canadian-based biopharmaceutical company focused on the development, manufacturing, and commercialization of cannabinoid-based products for medical and pharmaceutical applications. The company operates primarily within the biopharmaceutical, medical cannabis, and consumer health industries, with an emphasis on evidence-based formulations, regulatory compliance, and pharmaceutical-grade manufacturing standards. Avicanna’s core revenue drivers include medical cannabis products, cannabinoid-based pharmaceutical development, and proprietary topical and oral formulations.

Founded in 2016, Avicanna evolved from a research-focused cannabinoid developer into a vertically integrated platform encompassing R&D, manufacturing, and commercialization. The company has positioned itself as a science-driven operator with a strategic focus on regulated medical markets rather than recreational cannabis, leveraging clinical research, intellectual property, and international cultivation and supply arrangements to support its growth.

Business Operations

Avicanna operates through several core business lines, including Medical Cannabis, Pharmaceutical Development, and Consumer Health Products. Revenue is primarily generated through the sale of medical cannabis products under the RHO Phyto brand in Canada, contract manufacturing and formulation services, and the development of proprietary cannabinoid-based pharmaceutical candidates. The company emphasizes standardized dosing, physician engagement, and patient education as part of its commercialization model.

Operationally, Avicanna maintains domestic activities in Canada related to product formulation, commercialization, and regulatory oversight, while leveraging international operations for cultivation and raw material sourcing. The company controls intellectual property related to cannabinoid formulations and delivery mechanisms and has established partnerships and subsidiaries to support cultivation and extraction, including Santa Marta Golden Hemp, a joint venture in Colombia. Data inconclusive based on available public sources regarding the full extent of current active subsidiaries beyond publicly disclosed entities.

Strategic Position & Investments

Avicanna’s strategic direction centers on expanding its medical cannabis market share in Canada while advancing pharmaceutical-grade cannabinoid candidates through preclinical and clinical development. Growth initiatives include expanding physician-prescribed product offerings, enhancing patient access platforms, and increasing international sourcing efficiencies to improve margins and supply chain resilience.

The company has made targeted investments in international cultivation assets and research collaborations to support long-term pharmaceutical development. Avicanna continues to invest in emerging cannabinoid delivery technologies and regulated health products, with a stated focus on markets where medical cannabis frameworks and pharmaceutical regulations align. Data inconclusive based on available public sources regarding any large-scale acquisitions beyond previously announced joint ventures and platform investments.

Geographic Footprint

Avicanna is headquartered in Canada, where it maintains its primary corporate, regulatory, and commercialization operations. The company’s core commercial market is Canada, particularly within the federally regulated medical cannabis system, serving physicians, pharmacies, and registered patients nationwide.

Internationally, Avicanna has an operational and investment presence in Latin America, most notably Colombia, which serves as a strategic hub for cultivation and early-stage processing through joint venture arrangements. The company’s international footprint is designed to support global pharmaceutical supply chains rather than direct consumer sales in multiple jurisdictions.

Leadership & Governance

Avicanna is led by a management team with experience across pharmaceuticals, biotechnology, and regulated cannabis markets. The leadership emphasizes scientific validation, regulatory credibility, and long-term value creation through pharmaceutical development rather than short-term recreational market trends.

Key executives include:

• Aras Azadian – Chief Executive Officer
• Stephanie Karas – Chief Operating Officer
• Laura Tam – Chief Financial Officer
• Dr. Deepak Anand – Scientific Advisor

The company is governed by a board with experience in life sciences, capital markets, and international operations, supporting a strategic vision centered on medical legitimacy, research-driven product development, and disciplined international expansion.